Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02226965 · ClinicalTrials.gov registry record · Phase 2
PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)
A Phase 2 study of Lymphoma, Diffuse Large B-Cell, sponsored by Sierra Oncology LLC - a GSK company.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 20
- Study locations
NCT02226965: Completed Phase 2 study of Lymphoma, Diffuse Large B-Cell, sponsored by Sierra Oncology LLC - a GSK company.
NCT02226965 is a Phase 2 study of Lymphoma, Diffuse Large B-Cell that has completed, run by Sierra Oncology LLC - a GSK company. The registered enrollment target is 45 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (66% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02226965, a Phase 2 study of Lymphoma, Diffuse Large B-Cell, has completed, sponsored by Sierra Oncology LLC - a GSK company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It is a multi-center, nonrandomized, open label, phase II investigation of PNT2258 to characterize anti-tumor activity and collect safety data on patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma.
Primary Outcome
The proportion of patients with complete response (CR/complete metabolic response \[CMR\]) or partial response (PR/partial metabolic response \[PMR\]) according to the revised 2014 International Working Group (IWG) criteria for lymphoma (Cheson 2014)
Conditions Studied
Interventions
- DRUG PNT2258
Study Locations (20)
Michigan
- Mercy Health Saint Mary's - Grand Rapids
- St. John Hospital and Medical Center - Grosse Pointe Woods
- Michigan State University - Lansing
- William Beaumont Hospital - Royal Oak
California
- Long Beach Memorial Medical Center - Long Beach
- University of Southern California - Los Angeles
Florida
- Lynn Cancer Institute - Boca Raton
- Bond Clinic, P.A. - Winter Haven
Colorado
- Colorado Blood and Cancer Institute - Denver
Georgia
- Georgia Regents University - Augusta
Illinois
- Rush University Medical Center - Chicago
Indiana
- Horizon Oncology Research, Inc. - Lafayette
Louisiana
- UHC Oncology - Lafayette
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2014-12 |
| Est. Completion | 2018-08-22 |
| Phase | Phase 2 |
What the finished NCT02226965 record still lists
NCT02226965 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Lymphoma, Diffuse Large B-Cell appearing as the primary indexed condition, and to 1 intervention - of which PNT2258 is the first listed.
NCT02226965 names 20 study sites across 15 states, led by Michigan, California, Florida.
Frequently Asked Questions
What is clinical trial NCT02226965 about?
NCT02226965 is a clinical study titled "PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)". This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It is a multi-center, nonrandomized, open label, phase II investigation of PNT2258 to characterize anti-tumor activity and collect safety data on patients with relapsed or refractory (r/r) diffuse large B-cell lympho...
What is the current status of trial NCT02226965?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2014-12. Estimated completion is 2018-08-22.
What conditions does trial NCT02226965 study?
This clinical trial studies the following conditions: Lymphoma, Diffuse Large B-Cell.
What interventions are being tested in trial NCT02226965?
The interventions under investigation include: PNT2258 (DRUG).
Who is sponsoring clinical trial NCT02226965?
This trial is sponsored by Sierra Oncology LLC - a GSK company, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02226965 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02226965's enrollment target sits among peer trials
45 1296th of 2000 higher than 679 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia